A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer

BACKGROUND: Nonsmall cell lung cancer (NSCLC)-patients treated with standard chemotherapy experienced progression rapidly. A novel therapy based on programed death 1 (PD-1)/programed death ligand 1 (PD-L1) inhibitors showed an increasing potential in several malignancies including advanced NSCLC. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cuihua, Yu, Xuetao, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207545/
https://www.ncbi.nlm.nih.gov/pubmed/28033249
http://dx.doi.org/10.1097/MD.0000000000005539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207545/
https://www.ncbi.nlm.nih.gov/pubmed/28033249
http://dx.doi.org/10.1097/MD.0000000000005539

Ejemplares similares